Study Compares Effectiveness of Migraine Preventive Drugs
By Elana Gotkine HealthDay Reporter
FRIDAY, Dec. 22, 2023 -- For patients with migraine, simvastatin, calcitonin gene-related peptide pathway antibodies (CGRPabs), and amitriptyline have a favorable effect compared with beta blockers, according to a study published in the January issue of the European Journal of Neurology.
Marte H. Bjørk, M.D., Ph.D., from the University of Bergen in Norway, and colleagues estimated retention, defined as the number of uninterrupted treatment days, and effectiveness, defined as the reduction in filled triptan prescriptions during four 90-day periods after the first preventive prescription compared with a 90-day baseline period in 104,072 patients with migraine. Retention and efficacy were compared for different drugs against beta blockers.
The researchers found that botulinum toxin and CGRPabs were the least likely to be discontinued compared with beta blockers (hazard ratios, 0.43 and 0.63, respectively), while the most likely to be discontinued were clonidine and topiramate (hazard ratios, 2.95 and 1.34, respectively). The likelihood of achieving a clinically significant reduction in triptan use during the first 90 days of treatment was increased for those on simvastatin, CGRPabs, and amitriptyline, with propensity score-adjusted odds ratios of 1.28, 1.23 and 1.13, respectively.
"Our analysis shows that some established and cheaper medicines can have a similar treatment effect as the more expensive ones," Bjørk said in a statement. "This may be of great significance both for the patient group and Norwegian health care."
Several authors disclosed ties to pharmaceutical companies, including Novartis, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
Use of Acid-Suppression Therapy Linked to Migraine, Severe Headache
FRIDAY, April 26, 2024 -- Use of acid-suppression therapy is associated with higher odds of migraine or severe headache, according to a study published online April 24 in...
American Academy of Neurology, April 13-18
The annual meeting of the American Academy of Neurology was held this year from April 13 to 18 in Denver, drawing participants from around the world, including clinicians...
AAN: Half of Premenopausal Women Have Menstrual Migraines
FRIDAY, April 19, 2024 – More than half of premenopausal women report menstrual migraine (MM), according to a study presented at the annual meeting of the American Academy...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.